Rheumatoid Arthritis Drugs Market Size, Share Global Analysis Report, 2022 – 2030

Industry Insights

[231+ Pages Report] According to the report published by Facts and Factors, the global rheumatoid arthritis drugs market size was worth around USD 60.1 billion in 2021 and is predicted to grow to around USD 70.1 billion by 2030 with a compound annual growth rate (CAGR) of roughly 1.75% between 2022 and 2030. The report analyzes the global rheumatoid arthritis drugs market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the rheumatoid arthritis drugs market.

Market Overview

Rheumatoid arthritis is an autoimmune disorder that may either impact the joints or the surrounding areas of the human body. It is a chronic inflammatory disease and is capable of affecting body areas like the lungs, eyes, skin, blood vessels, and heart in advanced cases. When the immune system of a person mistakenly starts attacking the surrounding healthy body cells and tissues, an autoimmune disorder is set into motion. Rheumatoid arthritis differs from other arthritis forms like osteoarthritis in terms of the exact point it affects the body.

Unlike osteoarthritis, rheumatoid arthritis affects the joints lining resulting in painful swelling around the part and with time causes joint deformity and bone erosion. Inflammation associated with this type of arthritis is a critical factor as it can potentially impact other body parts as well. It is a progressive disease which means that with time it only gets worse and in rare cases, it may go into remission without any external help. However, the majority of the cases require the patients to undergo long treatments as the drugs can help control the progressiveness of the disease and help manage the associated symptoms.

Key Insights

• As per the analysis shared by our research analyst, the global rheumatoid arthritis drugs market is estimated to grow annually at a CAGR of around 1.75% over the forecast period (2022-2030)
• In terms of revenue, the global rheumatoid arthritis drugs market size was valued at around USD 60.1 billion in 2021 and is projected to reach USD 70.1 billion, by 2030.
• The market is projected to grow at a significant rate due to growing cases of rheumatoid arthritis
• Based on administration route channel segmentation, oral was predicted to show maximum market share in the year 2021
• Based on molecule segmentation, biopharmaceuticals were the leading molecule in 2021
• On the basis of region, North America was the leading revenue generator in 2021

Growth Drivers

• Growing cases of rheumatoid arthritis to propel market demand

The global rheumatoid arthritis drugs market is anticipated to witness a high growth rate owing to the growing number of rheumatoid arthritis cases across the globe. Certain symptoms associated with the disease include stiffness in joints which is at its peak during the morning hours causing severe pain, warm and swollen joints, loss of appetite, fever, and fatigue. Early onset can start from smaller joint areas, particularly in the joints that join the toes to the feet and fingers to the hand.

As per records, around 40% of rheumatoid arthritis patients may also witness symptoms in other body parts including nerve tissue, eyes, lungs, salivary glands, and skin. The signs and symptoms vary in intensity and may sometimes not exist at all. It is 2.5 times more common in females as compared to the male population and can start as early as 16 years of age and until 40 years.

As the cases are increasing, the global market players have increased the research activities surrounding the development and production of drugs to cater to the growing demands in the healthcare sector. Most commonly, Methotrexate is the first medicine given to a patient diagnosed with rheumatoid arthritis.

Restraints

• Associated side effects to restrict market expansion

The global market may face restraints during the growth period due to the prevalence of several side effects associated with the regular consumption of drugs to treat rheumatoid arthritis. Some patients have reported showing severe reactions including infection around injection areas, nausea, and headaches. Some lesser common unwanted effects of the drugs include tingling or numbness, shortness of breath, problems associated with vision, and heart failure which may be the most serious of all. Hence it is always recommended to get treatments from authorized personnel only and to stop taking the medication in case any of the effects are felt.

Opportunities

• Growing healthcare infrastructure in developing economies to provide growth opportunities

The global rheumatoid arthritis drugs market may witness high growth opportunities in the developing economies that are witnessing an influx of investments especially directed toward the healthcare segment. For instance, as per a report by the Organization for Economic Co-operation and Development, Brazil is projected to increase its health spending by 12.6% of the country’s gross domestic product (GDP) by 2040. As health concerns become a priority for every nation, the global market can expect more investments in the coming years.

Challenges

• Poor awareness rate to act as a major challenge

One of the key challenges faced by the global market players is in terms of inadequate or incorrect information amongst the population, especially in underdeveloped economies which are further pulled back by the absence of necessary infrastructure. In many countries, the population opts for non-medicinal ways to treat the conditions due to incorrect knowledge and accessibility to medical care.

Segmentation Analysis

The global rheumatoid arthritis drugs market is segmented based on administration route, sales channel, molecule, and region

Based on the administration route, the global market segments are oral and parenteral. In 2021, the highest revenue was in the oral segment as most of the medicines associated with the treatment of diseases can be taken orally along with other prescribed combination drugs.

However, to treat severe cases of rheumatoid arthritis doctors may recommend parenteral methods. In such conditions, an injection filled with methotrexate sodium solution is administered to the patient. Only doctors can inject the solution and the dose limit is once a week. The cost of an oral supply of methotrexate is around USD 43 for a pack of 20.

Based on the molecule, the global market divisions are biopharmaceuticals and pharmaceuticals with the former leading with the highest global market share. The biologics segment in biopharmaceuticals led the segmental growth with over 60%. These medicines originate from biological beings, unlike chemically synthesized drugs.

As the research on biomedicines grows due to lesser side effects associated with the drugs, investments in biologics for rheumatoid arthritis are projected to witness high growth. The biosimilar segment may grow owing to better availability of resources and favorable results at lower costs.

Recent Developments:

• In August 2022, Scientists and researchers at MedUni Vienna started working on a drug that can potentially revolutionize the treatment of rheumatoid arthritis as claimed by the community. They are currently in the Phase III trial of the drug
• In July 2021, after thoroughly analyzing the latest research on rheumatoid arthritis, the American College of Rheumatology (ACR) issued new guidelines for the treatment of the disease. The first draft was released in November 2020

Report Scope

Regional Analysis

• North America to register the highest growth in the coming years

The global rheumatoid arthritis drugs market is anticipated to witness the highest growth in North America owing to the growing research and developments of new drugs and treatment methods for the medical condition which affects nearly 1.3 million of the American population every year. The growing number of approvals from the US Food and Drugs Administration department may help the region witness higher growth.

In 2018, the institute approved the use of 2-milligram tablets of OLUMIANT® to treat rheumatoid arthritis in adults that suffer from moderate to severe forms of the condition. This can be given to the patient orally and only in cases where the patient has now shown any response to therapies involving the use of a tumor necrosis factor (TNF) inhibitor.

Competitor Analysis

• Regeneron Pharmaceuticals Inc. 
• Johnson & Johnson Services Inc. 
• Boehringer Ingelheim GmbH 
• Amgen Inc. 
• Novartis AG 
• F. Hoffmann-La Roche Ltd. 
• Bristol-Myers Squibb Company

The global rheumatoid arthritis drugs market is segmented as follows:

By Administration Route Segment Analysis

• Oral
• Parenteral

By Sales Channel Segment Analysis

• Over-The-Counter (OTC)
• Prescription

By Molecule Segment Analysis

• Biopharmaceuticals
  • Biologics
  • Biosimilars
• Pharmaceuticals

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic Countries
    • Denmark
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America